hVIVO (AIM: HVO ), the human challenge trial specialist, has reported substantial director share purchases by CEO Yamin ‘Mo’ Khan and CFO Stephen Pinkerton, suggesting management believes the current share price undervalues the business.
Khan acquired 3.3 million shares at 6.04p, while Pinkerton bought 520,000 shares at 5.5p, increasing their holdings to 1.21% and 0.19% of the company respectively. These follow earlier purchases at higher prices in mid-2025, adding weight to the latest move.
hVIVO, known for testing vaccines and antivirals using controlled human infection models, has continued to secure commercial contracts but has seen its share price weaken amid wider small-cap market pressure. These insider purchases, may offer a positive signal to retail investors, indicating strong internal confidence and alignment with shareholders.